Patients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...
Read moreWe explore why combination pricing is an issue in the oncology space and why payers and manufacturer...
Read moreAmgen’s Lumykras (sotorasib) has become the first active new technology to come through the Innova...
Read moreThe National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...
Read moreIn December 2021, China once again updated its National Reimbursed Drugs List (NRDL).
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreIn a statement the ICR said that it welcomes some of the changes, but that it wants to “see furthe...
Read moreWe hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth ...
Read moreThe use of combination therapy is increasingly becoming the standard of care in oncology as cancers ...
Read moreIn oncology, a hazard ratio (HR) is commonly used to estimate the treatment effect for survival endp...
Read more